Jake Van Naarden serves as the Executive Vice President and President of Loxo@Lilly at Eli Lilly and Company, a position he has held since joining the organization. With a robust background in the pharmaceutical industry, Jake has become a pivotal figure in driving the strategic direction and growth of Loxo@Lilly, Eli Lilly's oncology division. Prior to his current role, Jake held various leadership positions within the industry, where he honed his skills in oncology research and development, as well as in the commercialization of innovative cancer therapies. Under Jake's leadership, Loxo@Lilly has made significant strides in advancing the development of targeted cancer treatments. His vision and commitment to scientific excellence have been instrumental in bringing cutting-edge therapies to patients with unmet medical needs. Jake's strategic oversight has not only enhanced the division's research pipeline but also fostered collaborations that have accelerated the development of new treatments. His achievements at Eli Lilly are a testament to his dedication to improving cancer care and his ability to lead teams toward groundbreaking advancements in the field. In his role as Executive Vice President and President of Loxo@Lilly, Jake continues to steer the division's efforts in identifying and developing novel cancer therapies. His leadership is characterized by a patient-centric approach, ensuring that the therapies developed under his guidance are both effective and accessible. Jake's influence extends beyond Eli Lilly, as he is actively involved in industry-wide initiatives aimed at advancing cancer research and improving patient outcomes. His contributions to the field of oncology have solidified his reputation as a visionary leader committed to making a meaningful impact on the lives of cancer patients worldwide.